361 related articles for article (PubMed ID: 8755514)
1. RNA binding by the Wilms tumor suppressor zinc finger proteins.
Caricasole A; Duarte A; Larsson SH; Hastie ND; Little M; Holmes G; Todorov I; Ward A
Proc Natl Acad Sci U S A; 1996 Jul; 93(15):7562-6. PubMed ID: 8755514
[TBL] [Abstract][Full Text] [Related]
2. Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1.
Borel F; Barilla KC; Hamilton TB; Iskandar M; Romaniuk PJ
Biochemistry; 1996 Sep; 35(37):12070-6. PubMed ID: 8810912
[TBL] [Abstract][Full Text] [Related]
3. Characterization of RNA aptamer binding by the Wilms' tumor suppressor protein WT1.
Zhai G; Iskandar M; Barilla K; Romaniuk PJ
Biochemistry; 2001 Feb; 40(7):2032-40. PubMed ID: 11329270
[TBL] [Abstract][Full Text] [Related]
4. Overlapping RNA and DNA binding domains of the wt1 tumor suppressor gene product.
Bardeesy N; Pelletier J
Nucleic Acids Res; 1998 Apr; 26(7):1784-92. PubMed ID: 9512553
[TBL] [Abstract][Full Text] [Related]
5. Expression in Xenopus oocytes shows that WT1 binds transcripts in vivo, with a central role for zinc finger one.
Ladomery M; Sommerville J; Woolner S; Slight J; Hastie N
J Cell Sci; 2003 Apr; 116(Pt 8):1539-49. PubMed ID: 12640038
[TBL] [Abstract][Full Text] [Related]
6. Regulation of insulin-like growth factor I receptor gene expression by the Wilms' tumor suppressor WT1.
Werner H; Roberts CT; Rauscher FJ; LeRoith D
J Mol Neurosci; 1996; 7(2):111-23. PubMed ID: 8873895
[TBL] [Abstract][Full Text] [Related]
7. The Wilms' tumor suppressor, WT1, inhibits 12-O-tetradecanoylphorbol-13-acetate activation of the multidrug resistance-1 promoter.
McCoy C; McGee SB; Cornwell MM
Cell Growth Differ; 1999 Jun; 10(6):377-86. PubMed ID: 10392899
[TBL] [Abstract][Full Text] [Related]
8. Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1.
Drummond IA; Madden SL; Rohwer-Nutter P; Bell GI; Sukhatme VP; Rauscher FJ
Science; 1992 Jul; 257(5070):674-8. PubMed ID: 1323141
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the DNA binding characteristics of the related zinc finger proteins WT1 and EGR1.
Hamilton TB; Borel F; Romaniuk PJ
Biochemistry; 1998 Feb; 37(7):2051-8. PubMed ID: 9485332
[TBL] [Abstract][Full Text] [Related]
10. High affinity binding sites for the Wilms' tumour suppressor protein WT1.
Hamilton TB; Barilla KC; Romaniuk PJ
Nucleic Acids Res; 1995 Jan; 23(2):277-84. PubMed ID: 7862533
[TBL] [Abstract][Full Text] [Related]
11. Sequence and structural requirements for high-affinity DNA binding by the WT1 gene product.
Nakagama H; Heinrich G; Pelletier J; Housman DE
Mol Cell Biol; 1995 Mar; 15(3):1489-98. PubMed ID: 7862142
[TBL] [Abstract][Full Text] [Related]
12. EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity.
Scharnhorst V; Menke AL; Attema J; Haneveld JK; Riteco N; van Steenbrugge GJ; van der Eb AJ; Jochemsen AG
Oncogene; 2000 Feb; 19(6):791-800. PubMed ID: 10698497
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional repression of human insulin-like growth factor-II P4 promoter by Wilms' tumor suppressor WT1.
Lee YI; Kim SJ
DNA Cell Biol; 1996 Feb; 15(2):99-104. PubMed ID: 8634146
[TBL] [Abstract][Full Text] [Related]
14. Repression of promoters for the mouse insulin-like growth factor II-encoding gene (Igf-2) by products of the Wilms' tumour suppressor gene wt1.
Ward A; Pooler JA; Miyagawa K; Duarte A; Hastie ND; Caricasole A
Gene; 1995 Dec; 167(1-2):239-43. PubMed ID: 8566784
[TBL] [Abstract][Full Text] [Related]
15. A novel target for the Wilms' tumour suppressor protein (WT1) is bound by a unique combination of zinc fingers.
Little MH; Holmes G; Pell L; Caricasole A; Duarte A; Law M; Ward A; Wainwright B
Oncogene; 1996 Oct; 13(7):1461-9. PubMed ID: 8875984
[TBL] [Abstract][Full Text] [Related]
16. Wilms' tumor 1 splice variants have opposite effects on the tumorigenicity of adenovirus-transformed baby-rat kidney cells.
Menke AL; Riteco N; van Ham RC; de Bruyne C; Rauscher FJ; van der Eb AJ; Jochemsen AG
Oncogene; 1996 Feb; 12(3):537-46. PubMed ID: 8637710
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional repression of the insulin-like growth factor I receptor (IGF-I-R) gene by the tumor suppressor WT1 involves binding to sequences both upstream and downstream of the IGF-I-R gene transcription start site.
Werner H; Rauscher FJ; Sukhatme VP; Drummond IA; Roberts CT; LeRoith D
J Biol Chem; 1994 Apr; 269(17):12577-82. PubMed ID: 8175666
[TBL] [Abstract][Full Text] [Related]
18. DNA binding capacity of the WT1 protein is abolished by Denys-Drash syndrome WT1 point mutations.
Little M; Holmes G; Bickmore W; van Heyningen V; Hastie N; Wainwright B
Hum Mol Genet; 1995 Mar; 4(3):351-8. PubMed ID: 7795587
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of Wilms tumor WT1 splice variants on the insulin receptor promoter.
Webster NJ; Kong Y; Sharma P; Haas M; Sukumar S; Seely BL
Biochem Mol Med; 1997 Dec; 62(2):139-50. PubMed ID: 9441865
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Wilms tumor 1 transactivation by bone marrow zinc finger 2, a novel transcriptional repressor.
Lee TH; Lwu S; Kim J; Pelletier J
J Biol Chem; 2002 Nov; 277(47):44826-37. PubMed ID: 12239212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
